|
|
|
| Effect of Olanzapine on preventing vomiting in patients with breast cancer treated with Pirarubicin combined with Cyclophosphamide chemotherapy |
| HAN Yongqing FU Feng HUANG Kairong▲ |
| Department of Oncology, Shangrao People′s Hospital, Jiangxi Province, Shangrao 334000, China |
|
|
|
|
Abstract Objective To explore the effect of Olanzapine in the prevention of vomiting in breast cancer patients treated with Pirarubicin combined with Cyclophosphamide (AC) chemotherapy. Methods A total of 50 breast cancer patients who received AC chemotherapy in Shangrao People′s Hospital from January 2020 to March 2021 were selected as research subjects. They were divided into control group and observation group according to random number table method,with 25 cases in each group. The control group was treated with Ondansetron combined with Dexamethasone for prevention, the observation group was treated with Olanzapine for prevention on the basis of the control group. The acute, delayed complete remission (CR) rates of nausea and vomiting in the first cycle of chemotherapy and expected CR rate of nausea and vomiting in the second cycle of chemotherapy, the total incidence of extrapyramidal reaction after one cycle were compared between the two groups. Results There was no statistical significance in the rate of acute CR in the first cycle between the two groups (P＞0.05). There was no statistical significance in the rate of acute CR in the first cycle,delayed CR in the first cycle and expected CR in the second cycle in the observation group (P＞0.05). There was no statistical significance in the rate of delayed CR in the first cycle and expected CR in the second cycle in the observation group (P＞0.05). The rates of delayed CR in the first cycle and expected CR in the second cycle in the observation group were higher than those in the control group, the differences were statistically significant (P＜0.05). The delayed CR rate of the first cycle and the expected CR rate of the second cycle in the control group were lower than the acute CR rate of the first cycle, the differences were statistically significant (P＜0.05). There was no statistical significance between the delayed CR rate of the first cycle and the expected CR rate of the second cycle in the control group (P>0.05). There was no statistical significance in the total incidence of extrapyramidal reaction between the two groups (P>0.05). Conclusion Olanzapine is effective in preventing delayed and expected nausea and vomiting caused by AC chemotherapy in breast cancer patients, and does not increase the total incidence of extrapyramidal reactions.
|
|
|
|
|
|
| [1] |
上海市抗癌协会癌症康复与姑息专业委员会.化疗所致恶心呕吐全程管理上海专家共识（2018年版）[J].中国癌症杂志，2018，28（12）：946-960.
|
| [2] |
张冲.昂丹司琼与地塞米松联用对腹腔镜妇科手术术后恶心呕吐疗效分析[J].山西医药杂志，2019，48（7）：816-818.
|
| [3] |
郭蕊，张晋萍，丁选胜，等.奥氮平治疗高致吐化疗引起恶心呕吐的meta 分析[J].药学与临床研究，2018，26（1）：30-34.
|
| [4] |
杨锦，王倩荣，张俊美，等.培美曲塞联合铂类药物三线及以上治疗晚期乳腺癌的效果观察[J].中国肿瘤临床与康复，2020，27（10）：1185-1188.
|
| [5] |
李恩灿，范潇予，林琳，等.5-羟甲基糠醛及其二聚体OMBF引发Ⅰ型超敏反应毒性评价与机制初探[J].中国比较医学杂志，2020，30（2）：1-8.
|
| [6] |
皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0 版[J].肿瘤，2012，32（2）：142-144.
|
| [7] |
刘玉，高炳玉，夏立平，等.奥氮平在乳腺癌联合治疗方案中辅助化疗所致恶心呕吐的疗效观察[J].解放军药学学报，2017，33（2）：180-182.
|
| [8] |
赵秀芝，付艳萍，高鑫，等.帕洛诺司琼与昂丹司琼预防腹腔镜胆囊切除术后恶心、呕吐效果分析[J].临床军医杂志，2019，47（8）：851-852.
|
| [9] |
石亚飞，陈伟，王会凌，等.两种止吐药物预防CINV 的循证药物经济学评价[J].临床药物治疗杂志，2018，16（9）：14-18，28.
|
| [10] |
吴仲飞，秦学金，刘婧婧，等.四联方案预防高度致吐性化疗所致恶心呕吐的疗效观察[J].肿瘤药学，2019，9（3）：7：475-478，489.
|
| [11] |
董爽，王俊，胡胜，等.女性肺癌和乳腺癌患者中阿瑞匹坦与奥氮平预防多日化疗所致延迟性恶心呕吐的疗效观察[J].肿瘤防治研究，2017，44（5）：356-359.
|
| [12] |
朱玉英，贾勇圣，佟仲生.奥氮平治疗化疗所致恶心和呕吐的作用及临床研究进展[J].肿瘤，2018，38（1）：68-72.
|
| [13] |
程艳霞，邹敏，任林，等.奥氮平所致不良反应文献分析[J].中国医院药学杂志，2012，32（24）：2022-2024.
|
| [14] |
曾环思，钟彩妮，钟易霖，等.129 例奥氮平药品不良反应及血药浓度监测临床分析[J].中国药物警戒，2020，17（11）：818-822.
|
| [15] |
陈新蕾，郭灿璨.奥氮平在乳腺癌方案新辅助化疗所致恶心呕吐的应用价值[J].海峡药学，2019，31（7）：190-192.
|
|
|
|
